Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma
Author Department
Medicine
Document Type
Presentations, Research
Publication Date
5-1-2005
Recommended Citation
Fossella F, McCann JC, Tolcher A, Tie H, Hwang L, Carr C, Berg K, Fram R. Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. American Society of Clinical Oncology 41st Annual Meeting. Orlando, FL. May 13-May 17, 2005.
COinS